Circulating tumor DNA analysis may improve postoperative management for colorectal cancer.
Study indicates enhanced risk stratification and early relapse detection through ultradeep sequencing.
Assessment utilized ultradeep sequencing to analyze plasma cell-free DNA from patients with colorectal cancer stages I to III, providing crucial insights into their condition and treatment plans. This approach enables better monitoring of adjuvant chemotherapy in patients after surgery for colorectal cancer.
Abstract
Circulating tumor DNA analysis can potentially change the postoperative management of CRC by enabling risk stratification, ACT monitoring, and early relapse detection.